Repligen Co. (NASDAQ:RGEN) Shares Purchased by Retirement Systems of Alabama

Retirement Systems of Alabama raised its position in Repligen Co. (NASDAQ:RGENFree Report) by 0.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,204 shares of the biotechnology company’s stock after purchasing an additional 172 shares during the quarter. Retirement Systems of Alabama owned about 0.12% of Repligen worth $11,992,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in RGEN. O Shaughnessy Asset Management LLC purchased a new stake in Repligen in the third quarter valued at $385,000. Glenmede Trust Co. NA boosted its position in shares of Repligen by 24.2% during the 3rd quarter. Glenmede Trust Co. NA now owns 3,791 shares of the biotechnology company’s stock worth $603,000 after purchasing an additional 739 shares during the period. Advisors Asset Management Inc. increased its holdings in Repligen by 2.7% in the 3rd quarter. Advisors Asset Management Inc. now owns 12,550 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 328 shares during the last quarter. AXQ Capital LP acquired a new position in Repligen during the third quarter worth $273,000. Finally, Sei Investments Co. boosted its position in shares of Repligen by 34.6% during the third quarter. Sei Investments Co. now owns 251,877 shares of the biotechnology company’s stock worth $40,052,000 after buying an additional 64,774 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on RGEN shares. JPMorgan Chase & Co. decreased their target price on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and lowered their price objective for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. Finally, Guggenheim started coverage on shares of Repligen in a research note on Tuesday, June 18th. They set a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $193.00.

View Our Latest Stock Report on RGEN

Repligen Price Performance

Repligen stock opened at $120.08 on Friday. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The company has a fifty day simple moving average of $147.23 and a 200-day simple moving average of $171.98. The stock has a market cap of $6.71 billion, a P/E ratio of 480.34, a price-to-earnings-growth ratio of 4.04 and a beta of 0.95. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13.

Repligen (NASDAQ:RGENGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same period in the prior year, the company posted $0.64 earnings per share. The company’s revenue was down 17.1% compared to the same quarter last year. Equities analysts expect that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insider Activity

In related news, CEO Anthony Hunt acquired 2,000 shares of the firm’s stock in a transaction on Friday, June 14th. The stock was bought at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the completion of the purchase, the chief executive officer now directly owns 165,177 shares of the company’s stock, valued at approximately $20,495,162.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO Anthony Hunt acquired 2,000 shares of Repligen stock in a transaction on Friday, June 14th. The stock was bought at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the completion of the purchase, the chief executive officer now owns 165,177 shares in the company, valued at $20,495,162.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Martin D. Madaus bought 1,615 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was acquired at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the acquisition, the director now directly owns 4,613 shares in the company, valued at $576,348.22. The disclosure for this purchase can be found here. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Articles

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.